MODIFICATION OF CENTRAL DOPAMINERGIC MECHANISMS BY CONTINUOUS LEVODOPA THERAPY FOR ADVANCED PARKINSONS-DISEASE

被引:241
|
作者
MOURADIAN, MM
HEUSER, IJE
BARONTI, F
CHASE, TN
机构
[1] Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland
关键词
D O I
10.1002/ana.410270105
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
The management of fluctuations in motor function complicating advanced Parkinson's disease with continuously administered dopaminomimetics was studied in 12 patients. In response to 7 to 12 days of round‐the‐clock intravenous infusions of levodopa, fluctuations in motor performance gradually diminished, ultimately by more than 40°. The beneficial effect persisted for about 6 days after withdrawal of continuous parenteral treatment and resumption of standard oral therapy. Clinical improvement was associated with changes in several pharmacological indices: Acute dose‐response studies of intravenous levodopa showed a shift of the curve to the right in the immediate postinfusion phase compared to preinfusion studies; the therapeutic index improved significantly as patients demonstrated about 76° increased beneficial antiparkinsonian response with an equal degree of toxic dyskinetic effects; and the duration of action levodopa was prolonged by 30°. These results suggest that changes in central dopaminergic mechanisms contributing to motor complications in advanced Parkinson's disease can be modified by procedures that provide continuous dopamine replacement. Presumably these modifications underlie the gradual amelioration of motor fluctuations over several days of round‐the‐clock therapy. Results of the present study also suggest potential deleterious effects of chronic intermittent oral treatment in the development of motor complications and thus support the role of long‐term, continuous administration of dopaminomimetics. Copyright © 1990 American Neurological Association
引用
收藏
页码:18 / 23
页数:6
相关论文
共 50 条
  • [1] CONTINUOUS LISURIDE EFFECTS ON CENTRAL DOPAMINERGIC MECHANISMS IN PARKINSONS-DISEASE
    BARONTI, F
    MOURADIAN, MM
    DAVIS, TL
    GIUFFRA, M
    BRUGHITTA, G
    CONANT, KE
    CHASE, TN
    ANNALS OF NEUROLOGY, 1992, 32 (06) : 776 - 781
  • [2] CENTRAL MECHANISMS AND LEVODOPA RESPONSE FLUCTUATIONS IN PARKINSONS-DISEASE
    MOURADIAN, MM
    CHASE, TN
    CLINICAL NEUROPHARMACOLOGY, 1988, 11 (04) : 378 - 385
  • [3] LEVODOPA THERAPY IN PARKINSONS-DISEASE
    KOLLER, WC
    HUBBLE, JP
    NEUROLOGY, 1990, 40 (10) : 40 - 47
  • [4] CONTINUOUS DOPAMINERGIC STIMULATION IN PARKINSONS-DISEASE
    OBESO, JA
    LUQUIN, MR
    VAAMONDE, J
    GRANDAS, F
    LAGE, JMM
    CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES, 1987, 14 (03) : 488 - 492
  • [5] LEVODOPA THERAPY FEATURES IN PARKINSONS-DISEASE
    POLLAK, P
    GAZETTE MEDICALE, 1985, 92 (37): : 83 - 86
  • [6] MORTALITY IN PARKINSONS-DISEASE AND ITS MODIFICATION BY LEVODOPA
    SCHNEIDER, E
    FISCHER, PA
    JACOBI, P
    KOLB, R
    FORTSCHRITTE DER NEUROLOGIE PSYCHIATRIE, 1981, 49 (05) : 187 - 192
  • [7] RESULT OF CHRONIC LEVODOPA THERAPY AND ITS MODIFICATION BY BROMOCRIPTINE IN PARKINSONS-DISEASE
    HOEHN, MMM
    ACTA NEUROLOGICA SCANDINAVICA, 1985, 71 (02): : 97 - 106
  • [8] EXPERIENCE WITH SELEGILINE AND LEVODOPA IN ADVANCED PARKINSONS-DISEASE
    LIEBERMAN, A
    FAZZINI, E
    ACTA NEUROLOGICA SCANDINAVICA, 1991, 84 : 66 - 69
  • [9] PHARMACOKINETICS AND EFFECTS OF LEVODOPA IN ADVANCED PARKINSONS-DISEASE
    BREDBERG, E
    TEDROFF, J
    AQUILONIUS, SM
    PAALZOW, L
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1990, 39 (04) : 385 - 389
  • [10] CHOLINERGIC AND DOPAMINERGIC MECHANISMS IN PARKINSONS-DISEASE AFTER LONG-TERM LEVODOPA ADMINISTRATION
    YAHR, MD
    CLOUGH, CG
    BERGMANN, KJ
    LANCET, 1982, 2 (8300): : 709 - 710